Loading…
Loading…
See exactly how LEAD's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LEAD and 80,000+ other tickers.
Siren ETF Trust - Siren DIVCON Leaders Dividend ETF is an exchange traded fund launched and managed by SRN Advisors, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across diversified sectors. It invests in growth and value stocks of large-cap companies. The fund invests in dividend paying stocks of companies. The fund seeks to track the performance of the Siren DIVCON Leaders Dividend Index and S&P 500 Total Return Index, by using full replication technique. Siren ETF Trust - Siren DIVCON Leaders Dividend ETF was formed on January 6, 2016 and is domiciled in the United States.
HUNTINGDON VALLEY, Pa., July 1, 2026 /PRNewswire/ -- The Board of Trustees of Siren ETF Trust (the "Trust") has determined to close and liquidate the Siren DIVCON Leaders Dividend ETF (CBOE: LEAD) and Siren NexGen Economy ETF (NASDAQ: BLCN), each of which is a series of the Trust (each, a "Fund").
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Integer (ITGR) To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- SRN Advisors, LLC (SRN) announced today that the Siren DIVCON Dividend Defender ETF (CBOE: DFND), an index-based exchange-traded fund ("ETF")
LEAD is comprised of dividend-paying U.S. stocks with a high likelihood of increasing their dividend payments, as determined by a proprietary system. However, LEAD holds mostly low-yielding stocks, making it a unique offering that's best compared with broad-based funds like SPY. Its expected yield is only 0.77%. Using SPY as a comparator, LEAD's total returns were about 34% less since its January 2016 launch. With low-single-digit dividend growth rates, I don't see the appeal.
NARI: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Inari Medical, Inc. May 20, 2024 10:00 AM EDT | Source: Kessler Topaz Meltzer & Check, LLP Radnor, Pennsylvania--(Newsfile Corp. - May 20, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Inari Medical, Inc. ("Inari Medical") (NASDAQ: NARI) on behalf of investors who purchased or acquired Inari Medical common stock between February 24, 2022 through February 28, 2024, inclusive (the "Class Period"). The action charges Inari Medical with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Inari Medical's materially misleading statements and omissions to the public, Inari Medical's investors have suffered significant losses.The lead plaintiff deadline is July 12, 2024. If you suffered Inari Medical losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/inari-medical-inc?utm_source=PR&utm_medium=link&utm_campaign=nari&mktm=rYou can also contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCTOn February 28, 2024, Inari Medical revealed in its Form 10-K for fiscal year 2023 that the company had received a civil investigative demand from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents primarily relating to meals and consulting service payments provided to health care professionals.Following this news, Inari Medical's stock price plummeted over $12 per share, or 21% the very next trading day, from a closing price of $58.26 per share on February 28, 2024, to $46.12 per share on February 29, 2024 - wiping out approximately $700 million in market capitalization in one trading day.WHAT CAN I DO?Inari Medical investors may, no later than July 12, 2024, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Inari Medical investors who have suffered significant losses to contact the firm directly to acquire more information. The class action complaint against Inari Medical, Michiana Area Electrical Workers' Pension Fund v. Inari Medical, Inc., et al., Case No. 24-cv-03686, is filed in the United States District Court for the Southern District of New York and is pending before the Honorable Jennifer Hutchison Rearden.CLICK HERE TO SIGN UP FOR THE CASE or go to: https://www.ktmc.com/new-cases/inari-medical-inc?utm_source=PR&utm_medium=link&utm_campaign=nari&mktm=rWHO CAN BE A LEAD PLAINTIFF?A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.ABOUT KESSLER TOPAZ MELTZER & CHECK, LLPKessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.CONTACT:Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.(484) 270-1453280 King of Prussia RoadRadnor, PA 19087info@ktmc.comMay be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209807 SOURCE: Kessler Topaz Meltzer & Check, LLP